First line hypertension drug
Reading File
Searching PubMed
"hypertension" AND "first-line" AND "antihypertensive"
Finding Sources
Searching the Web
first line hypertension drugs 2024 2025 guidelines JNC AHA ACC
Finding Sources
Reading File
Reading File
Here is a thorough, guideline-based summary of first-line antihypertensive drugs:
First-Line Drugs for Hypertension
Per the 2025 AHA/ACC Guidelines (full guideline, Circulation 2025;152:1-105), four drug classes are recommended as first-line therapy for primary (essential) hypertension:
The Four First-Line Classes
| Class | Prototype Examples | Typical Dose Range | Key Notes |
|---|---|---|---|
| Thiazide/Thiazide-like Diuretics | Hydrochlorothiazide, Chlorthalidone, Indapamide | 12.5-50 mg/day | Chlorthalidone preferred over HCTZ (longer acting, better outcomes data) |
| Long-acting Dihydropyridine CCBs | Amlodipine, Nifedipine ER | Amlodipine 2.5-10 mg/day | Excellent for elderly and isolated systolic HTN |
| ACE Inhibitors (ACEi) | Ramipril, Lisinopril, Enalapril | Lisinopril 10-40 mg/day | Mandatory in CKD with proteinuria, diabetes; avoid in pregnancy |
| Angiotensin Receptor Blockers (ARBs) | Losartan, Valsartan, Olmesartan | Losartan 50-100 mg/day | Use when ACEi causes intolerable cough; never combine ACEi + ARB |
Do NOT combine ACEi + ARB - the 2025 guidelines classify this as Class 3: Harm.
Dosing Algorithm by Stage
- Stage 1 HTN (SBP 130-139 / DBP 80-89 mmHg): Start with 1 first-line agent, titrate dose and add others sequentially as needed. Pharmacological treatment depends on CV risk - not always required.
- Stage 2 HTN (SBP ≥140 / DBP ≥90 mmHg): Start with 2 first-line agents of different classes, ideally as a single-pill combination to improve adherence.
Why Beta-Blockers Are NOT First-Line
Per Goldman-Cecil Medicine and Katzung's Pharmacology, beta-blockers were removed from first-line status because they are:
- Generally less effective at lowering BP than the four preferred classes
- Less protective against stroke compared to CCBs and thiazides
- Still indicated when a compelling indication exists (e.g., post-MI, heart failure with reduced ejection fraction, atrial fibrillation)
Comorbidity-Driven Drug Selection
Per Goodman & Gilman's and the 2025 AHA/ACC guideline:
| Comorbidity | Preferred Agent(s) |
|---|---|
| CKD with proteinuria / Diabetes | ACEi or ARB (first choice) |
| Coronary artery disease | ACEi or ARB + Beta-blocker |
| Heart failure (HFrEF) | ACEi/ARB + Beta-blocker + MRA |
| Elderly / Isolated systolic HTN | CCB or Thiazide |
| Stroke/TIA history | ACEi + Thiazide diuretic |
| Left ventricular hypertrophy | ACEi, ARB, or CCB |
| Pregnancy | Labetalol or Nifedipine ER (ACEi/ARB are contraindicated) |
| Peripheral artery disease | ACEi or ARB |
| Benign prostatic hypertrophy | Alpha-1 blocker (doxazosin) - 2nd line adjunct |
Key Points from Pharmacology Textbooks
- Blood pressure lowering itself is the most important goal - large trials showed no major differences in outcome between the four classes in uncomplicated HTN (Goodman & Gilman's, 16th ed.)
- All four classes are available as low-cost generics, making cost a non-issue
- Prefer drugs with long half-lives (once-daily dosing) to improve compliance and achieve >50% trough-peak effect ratio
- Non-pharmacological therapy first: sodium restriction (<70-100 mEq/day), weight loss, DASH diet, exercise - these can normalize BP in up to 75% of overweight patients with mild-moderate HTN (Katzung, 16th ed.)
Sources: Katzung's Basic & Clinical Pharmacology (16e), Goodman & Gilman's Pharmacological Basis of Therapeutics, 2025 AHA/ACC Hypertension Guideline, NYC DOH 2025 Advisory
This is a shared conversation. Sign in to Orris to start your own chat.